New Options in Platinum Resistant Ovarian Cancer-Recording

Video Transcription

Video Summary

In this video, Dr. Wendell Naumann and Dr. David O'Malley discuss new options in platinum-resistant ovarian cancer. The webinar is sponsored by an educational grant from Imogene. Dr. Naumann is a gynecologic oncologist at the Levine Cancer Institute, and Dr. O'Malley is a professor and director of the division of G1 Oncology and co-director of the G1 Oncology phase one program at Ohio State University. They discuss various treatment options for platinum-resistant ovarian cancer, including platinum doublets, bevacizumab (BEV), and antibody-drug conjugates like mirvetuximab soravtansine (MIRV). They also highlight the importance of clinical trials in identifying novel therapies. Dr. O'Malley presents data from the Forward II trial, which investigated the efficacy of MIRV-BEV in platinum-resistant ovarian cancer. The trial demonstrated a 44% objective response rate with a median duration of response of almost 10 months. Dr. Naumann emphasizes the importance of treating hypertension associated with BEV therapy to minimize treatment discontinuation. They also discuss the future potential of MIRV in first-line treatment and the reversibility of ocular toxicity associated with MIRV-BEV. The video concludes with a reminder about the upcoming deadline for abstract submissions for the 2023 meeting of the International Gynecologic Cancer Society in Seoul, Korea. The webinar recording will be available on the IGCS 360 platform for viewing later.

Keywords

platinum-resistant ovarian cancer

treatment options

bevacizumab

mirvetuximab soravtansine

clinical trials

objective response rate

International Gynecologic Cancer Society